DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
If you are interested in DXCM stock information, you might also be interested in competitors like NasdaqGS:HON.
With a P/E ratio of 103.08, the stock appears relatively expensive compared to its index ^SPX at the moment.
The market capitalization of DexCom is currently at $35.27 B. This places it among the high capitalized companies.
The book value reported in the balance sheet results in a P/B ratio of 15.62.
With one share of DexCom investors achieved a dividend of $0.00. This results in a very low dividend yield of 0.00%.
For the risk analysis, the high beta factor should be noted, which is currently at a value of 1.02. The price of the stock NasdaqGS:DXCM is therefore subject to relatively strong fluctuations in relation to the overall market.
0.47% of DXCM Stocks is owned by insiders.
For Wall Street analysts, a price target of $120.89 is currently considered realistic.
NasdaqGS:DXCM has a 52 week range of $66.89 - $164.86 and is currently trading around $89.83.
The low short sale ratio indicated that the value might increase in the foreseeable future.